David Wulliman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7962262/publications.pdf

Version: 2024-02-01

1478505 1720034 7 321 6 7 citations h-index g-index papers 8 8 8 406 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial. Haematologica, 2022, 107, 1000-1003.	3.5	14
2	NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals. Molecular Medicine, 2022, 28, 20.	4.4	18
3	Elevated CD21low B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency. Journal of Clinical Immunology, 2022, 42, 716-727.	3.8	13
4	MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine. Molecular Medicine, 2022, 28, 54.	4.4	18
5	The Karolinska <scp>KI</scp> /K <scp>COVID</scp> ‶9 immune atlas: An open resource for immunological research and educational purposes. Scandinavian Journal of Immunology, 2022, 96, .	2.7	4
6	Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine, 2021, 74, 103705.	6.1	161
7	Cytotoxic T-cells mediate exercise-induced reductions in tumor growth. ELife, 2020, 9, .	6.0	93